|
MediciNova completes enrollment in Phase II asthma trial
Pharmaceutical Business Review MediciNova has completed enrollment in its Phase II trial (MN-221-CL-007) evaluating the safety and efficacy of MN-221 for treatment of acute exacerbations of asthma. The randomized, double-blind trial enrolled a total of 176 asthma patients in the … MediciNova Completes Enrollment in Phase 2 MN-221 Trial Treating Patients … |
View full post on asthma – Google News